MCM2 and cholangiocarcinoma: In colon cancer, CACYBP enhances proliferation by interacting with Skp1 to degrade p27ˆKip1 [30], while in cholangiocarcinoma, it promotes progression by inhibiting MCM2 ubiquitination and activating the Wnt/β-catenin signaling pathway [13].